H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Seagen on Friday, setting a price target of $200, which is approximately 43.65% above the present share price of $139.23.
Fein expects Seagen to post earnings per share (EPS) of $0.93 for the second quarter of 2021.
The current consensus among 14 TipRanks analysts is for a Moderate Buy rating of shares in Seagen, with an average price target of $184.17.
The analysts price targets range from a high of $254 to a low of $145.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $601.29 million and a net profit of $164.99 million. The company's market cap is $25.24 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.8% and a 51.12% success rate.
Washington-based Seagen, Inc. is a biotechnology company, which is focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev.